Staci Swiderski, CEO and Founder of Family Source Consultants, shares her excitement about the partnership with Worth the Wait Charity as she is deeply moved by their mission of easing the financial burden for young adult cancer survivors pursuing parenthood, given her own personal connection to the cause.
After undergoing a partial hysterectomy in 1998 due to suspected uterine cancer, Swiderski and her husband turned to surrogacy to build their family. Inspired by their experience, Swiderski established Family Source Consultants to assist other intended parents begin their journey to parenthood via surrogacy.
Worth the Wait was founded in June 2021 by Mike and Megan Scherer. Just three years into their marriage, Mike was diagnosed with testicular cancer. After surgery in 2011 and chemo in 2012, he was declared cancer free. Their road to parenthood included the challenge of infertility, but they became parents in 2017. Their son’s arrival proved WORTH THE WAIT!
Hosted by Joy Rejholec, Chief Administrative Officer, Family Source Consultants
Staci Swiderski, CEO and owner of Family Source Consultants, has been a prominent leader in reproductive medicine for over two decades. Through her strategic vision and dedication, she has developed Family Source Consultants into a globally recognized agency specializing in comprehensive egg donation and gestational surrogacy services. Under Staci’s leadership, the agency has become a trusted partner for intended parents, surrogates, and egg donors worldwide, known for its rigorous standards, compassionate support, and commitment to excellence in third-party reproduction.
Her professional insight is uniquely informed by her own family-building experiences. As an intended parent, Staci welcomed her son via gestational surrogacy in 2005, and as a known egg donor, she assisted an infertile couple in expanding their family. These experiences lend a rare depth to her leadership and have fueled her ongoing dedication to ethical, empathetic, and professional support within the field of reproductive medicine.